Express News | Yangpu Medical: Wholly-owned subsidiary obtained environmental management system certification
Yangpu Healthcare (300030.SZ) announced first-quarter results, turning profit into loss to $3.19,900
Yangpu Medical (300030.SZ) released its report for the first quarter of 2024. The company's revenue was 1.41...
The medical device sector declined at the beginning. Xiangyu Medical fell by more than 10%, while Beautiful Healthcare, Bohui Innovation, Aibang Healthcare, Lanwei Medicine, and Yangpu Healthcare followed suit.
The medical device sector declined at the beginning. Xiangyu Medical fell by more than 10%, while Beautiful Healthcare, Bohui Innovation, Aibang Healthcare, Lanwei Medicine, and Yangpu Healthcare followed suit.
Express News | Yangpu Medical: Authorized Director Mr. Jiang Guangcheng to act as legal representative, chairman and general manager
Yangpu Healthcare plummeted 13% in a single day: the chairman was filed, and his wife was involved in insider trading
According to the administrative penalty decision ([2019] No. 66) issued by the Securities Regulatory Commission on July 8, 2019, the CSRC determined that Zhang Hong, the wife of Yang Pu Medical Chairman Deng Guanhua, had the illegal facts of forming and disclosing insider information and using the “Zhang Mouxiang” account to trade “Yangpu Healthcare” insiders, and decided to confiscate Zhang Hong's illegal proceeds of 9.4463 million yuan and imposed a fine of 283.39 million yuan.
Express News | Yangpu Healthcare dropped by more than 10%, and Chairman and General Manager Deng Guanhua was investigated and placed in custody.
Yangpu Medical (300030.SZ): Chairman and General Manager Deng Guanhua was investigated and placed in custody
Yangpu Medical (300030.SZ) announced that the company recently received the “Notice of Case Filing” and “Notice of Detention” issued by the Guangdong Provincial Supervisory Commission. Deng Guanhua, the chairman and general manager of the company, was investigated and placed in detention due to suspected disciplinary offenses.
Express News | Yangpu Healthcare: Chairman and General Manager Deng Guanhua was investigated and placed in custody
Yangpu Healthcare (300030.SZ): As of February 8, 2024, the total number of shareholders of the company was about 26,600
Gelonghui, Feb. 19 | Yangpu Medical (300030.SZ) said on an interactive platform that as of February 8, 2024, the total number of shareholders of the company was about 26,600.
Yangpu Medical (300030.SZ) issued an advance loss, with an estimated net loss of 45 million yuan to 65 million yuan in 2023
Yangpu Healthcare (300030.SZ) disclosed its 2023 annual results forecast. The company is expected to belong to listed company shares...
Yangpu Healthcare (300030.SZ): As of December 20, 2023, the total number of shareholders of the company was about 27,400
On December 25, Gelonghui, Yangpu Medical (300030.SZ) said on an interactive platform that according to data provided by China Securities Registration and Settlement Co., Ltd., as of December 20, 2023, the total number of shareholders of the company was about 27,400.
Yangpu Medical (300030.SZ): There are currently no relevant testing products
On November 27, Gelonghui, some investors asked Yangpu Healthcare (300030.SZ) on the investor interactive platform, “Now that mycoplasma infection and the virus are superimposed on it, the company has any testing products used to improve prevention and service to the community.” The company replied that the company currently has no relevant testing products.
Yangpu Medical (300030.SZ) released the first three quarter results, net profit increased by 105.51%
Yangpu Medical (300030.SZ) released its report for the third quarter of 2023, and achieved revenue of 4.7 in the first three quarters...
Yangpu Medical (300030.SZ): The company is currently the only domestic vacuum blood collection company registered by the US FDA
Gelonghui September 18 | Yangpu Medical (300030.SZ) said at an investor relations event on September 18 that the company is a leading enterprise in the domestic vacuum blood collection system industry, and is currently the only domestic vacuum blood collection company registered with the US FDA. After nearly 30 years of development, the company has a team of professional blood testing experts, has accumulated a deep academic heritage in the field of blood, and has a good academic reputation, including participating in the formulation and revision of national standards and industry standards for products such as vacuum blood collection tubes and thromboelastography. It is one of the main drafters of the standards.
Express News | Yangpu Medical: The application documents for withdrawing a fixed capital increase of 156 million yuan will be re-declared in due course according to market conditions
Yangpu Medical (300030.SZ) withdrew its application and increased the application documents through simplified procedures
Yangpu Medical (300030.SZ) announced that the fourth session of the sixth board of directors of the company was held on September 4, 2023...
Yangpu Medical (300030.SZ) released the first half of the year results, turning a loss into a profit of 10.464,400 yuan
Yangpu Medical (300030.SZ) released the 2023 semi-annual report. During the reporting period, the company achieved operating income...
Yangpu Healthcare (300030.SZ): Real estate rights and ancillary facilities under the name of Yangpu in Chenzhou to be withdrawn, the transaction amount is about 597.729 million yuan
Yangpu Medical (300030.SZ) announced that on August 16, 2023, the company's wholly-owned subsidiary Chenzhou Yangpu...
Yangpu Medical (300030.SZ): The company is developing an AI-based fully automated thromboelastography system project and a molecular diagnostic blood collection vessel construction project
GLONGHUI July 24丨Some investors asked Xiang Yangpu Healthcare (300030.SZ): How is the company's R&D investment? What are the R&D results? Yangpu Medical replied: The company attaches importance to R&D and continues to promote technological innovation. In 2022, the company's R&D investment accounted for 6.14% of revenue, up 0.61 percentage points from the same period last year. At the same time, the company is based on independent R&D and innovation, and most of the R&D team are professionals in the fields of biochemistry and clinical medicine. In 2022, the company and subsidiaries obtained 24 new patent authorizations, including 3 invention patents and 20 utility models in China
Yangpu Healthcare (300030.SZ): Many of the company's products have EU CE certification, US FDA certification, and market entry qualifications from Canada, Brazil and other countries
Glonway July 24丨Some investors asked Xiang Yangpu Healthcare (300030.SZ): What are the certifications in Europe and the US? What is the layout of overseas markets? Yangpu Medical's response: Many of the company's products have EU CE certification, US FDA certification, and market entry qualifications from Canada, Brazil and other countries. The company's quality system can also meet the requirements of ISO9001, ISO13485, QSR820, MDD, MDR, IVDR and MDSAP quality management systems. The market covers more than 100 countries and regions around the world, providing products and technology for nearly 10,000 well-known medical institutions
No Data